Indian stocks: Visit www.stage2stocks.com →

PharmaCyte Biotech, Inc.

Stage 4 · Declining · week 14

As of Oct 22, 2026, PharmaCyte Biotech is in Stage 4, the downtrend phase, now in week 14 (since Jul 17, 2026). It closed at $0.35, 71.3% below its 52-week high and below its 200-day average, which is falling.

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. More about the company

$0.35
+0.78% today
$3.8M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is PMCB early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 18w
S4 23w
S4 29w
S4 14w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 18w → S1 9w → S4 6w → S1 7w → S2 1w → S1 1w → S4 23w → S1 4w → S4 13w → S1 3w → S4 29w → S1 3w → S4 12w → S1 2w → S4 11w → S1 10w → S4 14w current
Total tracked: 165 weeks across 17 stage runs.

PMCB among Biotechnology405th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…405PMCBStage 4 · wk 1417−18.3%
vs 52W High
-71.3%
$0.34 lo$1.22 hi
71.3% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 14
1w13w26w
Week 14, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-47.1%
200 DMA: $0.66 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.15x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-18.3%
3M
-41.7%
6M
-53.3%
YTD
-52.6%
1Y
-64.2%
Scan Membership
Breakout Watch
Latest: 2024-05-23
5 appearances in last 60 days. First seen: 2020-01-10.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 14 · Vol 0.15x
2026-10-21S4
Wk 14 · Vol 0.24x
2026-10-20S4
Wk 14 · Vol 0.11x
2026-10-19S4
Wk 14 · Vol 0.12x
2026-10-16S4
Wk 13 · Vol 0.15x
2026-10-15S4
Wk 13 · Vol 0.25x
2026-10-14S4
Wk 13 · Vol 0.18x
2026-10-13S4
Wk 13 · Vol 0.27x
2026-10-12S4
Wk 13 · Vol 0.52x
2026-10-09S4
Wk 12 · Vol 0.40x
2026-10-08S4
Wk 12 · Vol 0.92x
2026-10-07S4
Wk 12 · Vol 0.42x
Moving averages & range
50 DMA
$0.44
200 DMA
$0.66
52W High
$1.22
52W Low
$0.34
5D Low
$0.34
Resistance levels (recent highs)
20d High
$0.44
60d High
$0.60
120d High
$0.95
250d High
$1.22
Next resistance
+26.0%
to 20d High
ROE
-44.0%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.1

PharmaCyte Biotech: quick answers

What stage is PharmaCyte Biotech in?

As of Oct 22, 2026, PharmaCyte Biotech (PMCB) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 17, 2026 and is in week 14. What the four stages mean

Is PharmaCyte Biotech in an uptrend?

No. PharmaCyte Biotech is in a Stage 4 downtrend. It trades 47.1% below its 200-day average, which is falling.

How far is PharmaCyte Biotech from its 52-week high?

PharmaCyte Biotech closed at $0.35 on Oct 22, 2026, 71.3% below its 52-week high of $1.22. Its 52-week low is $0.34.

How has PharmaCyte Biotech performed over the past year?

As of Oct 22, 2026, PharmaCyte Biotech is down 64.2% over the past year and down 52.6% so far in 2026.

Which sector and industry is PharmaCyte Biotech in?

PharmaCyte Biotech is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.